# AdaptHealth Corp.: financial statements, quarterly

AHCO · Nasdaq · CIK 1725255 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ahco.md) · [Financials](/companies/ahco/financials.md) · [Filings](/companies/ahco/filings.md) · [Insiders](/companies/ahco/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ahco/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [804](/filings/0001628280-24-045365.md) | [858 d](/filings/0001628280-26-011213.md) | [792](/filings/0001628280-25-022716.md) | [806](/filings/0001628280-25-037931.md) | [806](/filings/0001628280-25-048944.md) | [857 d](/filings/0001628280-26-011213.md) | [778](/filings/0001628280-26-030602.md) | [657](/filings/0001628280-26-052646.md) | [820](/filings/0001628280-25-048944.md) | [846 d](/filings/0001628280-26-011213.md) | [820](/filings/0001628280-26-030602.md) | [740](/filings/0001628280-26-052646.md) |
| Cost of revenue | $m | [693](/filings/0001628280-24-045365.md) | [554 d](/filings/0001628280-26-011213.md) | [635](/filings/0001628280-25-022716.md) | [637](/filings/0001628280-25-037931.md) | [644](/filings/0001628280-25-048944.md) | [664 d](/filings/0001628280-26-011213.md) | [657](/filings/0001628280-26-030602.md) | [521](/filings/0001628280-26-052646.md) | [658](/filings/0001628280-25-048944.md) | [674 d](/filings/0001628280-26-011213.md) | [708](/filings/0001628280-26-030602.md) | [636](/filings/0001628280-26-052646.md) |
| Operating income | $m | [(461)](/filings/0001628280-24-045365.md) | [(218) d](/filings/0001628280-26-011213.md) | [50.5](/filings/0001628280-25-022716.md) | [52.0](/filings/0001628280-25-037931.md) | [63.5](/filings/0001628280-25-048944.md) | [97.7 d](/filings/0001628280-26-011213.md) | [23.2](/filings/0001628280-26-030602.md) | [65.7](/filings/0001628280-26-052646.md) | [61.7](/filings/0001628280-25-048944.md) | [(73.3) d](/filings/0001628280-26-011213.md) | [5.5](/filings/0001628280-26-030602.md) | [(138)](/filings/0001628280-26-052646.md) |
| Interest expense | $m | [32.3](/filings/0001628280-23-037441.md) | [33.5 d](/filings/0001628280-24-007254.md) | [32.5](/filings/0001628280-24-021191.md) | [33.0](/filings/0001628280-24-035235.md) | [31.4](/filings/0001628280-24-045365.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(34.6)](/filings/0001628280-24-045365.md) | [(18.1) d](/filings/0001628280-26-011213.md) | [6.6](/filings/0001628280-25-022716.md) | [7.2](/filings/0001628280-25-037931.md) | [8.1](/filings/0001628280-25-048944.md) | [19.3 d](/filings/0001628280-26-011213.md) | [0.9](/filings/0001628280-26-030602.md) | [32.8](/filings/0001628280-26-052646.md) | [10.6](/filings/0001628280-25-048944.md) | [3.5 d](/filings/0001628280-26-011213.md) | [(5.2)](/filings/0001628280-26-030602.md) | [(21.2)](/filings/0001628280-26-052646.md) |
| Net income | $m | [(454)](/filings/0001628280-24-045365.md) | [(255) d](/filings/0001628280-26-011213.md) | [(2.1)](/filings/0001628280-25-022716.md) | [19.4](/filings/0001628280-25-037931.md) | [22.9](/filings/0001628280-25-048944.md) | [50.3 d](/filings/0001628280-26-011213.md) | [(7.2)](/filings/0001628280-26-030602.md) | [14.7](/filings/0001628280-26-052646.md) | [24.5](/filings/0001628280-25-048944.md) | [(103) d](/filings/0001628280-26-011213.md) | [(16.0)](/filings/0001628280-26-030602.md) | [(134)](/filings/0001628280-26-052646.md) |
| Diluted EPS | $ per share | [(3.43)](/filings/0001628280-24-045365.md) | not reported | [(0.02)](/filings/0001628280-25-022716.md) | [0.13](/filings/0001628280-25-037931.md) | [0.15](/filings/0001628280-25-048944.md) | not reported | [(0.05)](/filings/0001628280-26-030602.md) | [0.10](/filings/0001628280-26-052646.md) | [0.16](/filings/0001628280-25-048944.md) | not reported | [(0.12)](/filings/0001628280-26-030602.md) | [(0.99)](/filings/0001628280-26-052646.md) |
| Basic EPS | $ per share | [(3.37)](/filings/0001628280-24-045365.md) | not reported | [(0.02)](/filings/0001628280-25-022716.md) | [0.13](/filings/0001628280-25-037931.md) | [0.16](/filings/0001628280-25-048944.md) | not reported | [(0.05)](/filings/0001628280-26-030602.md) | [0.10](/filings/0001628280-26-052646.md) | [0.17](/filings/0001628280-25-048944.md) | not reported | [(0.12)](/filings/0001628280-26-030602.md) | [(0.99)](/filings/0001628280-26-052646.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [585](/filings/0001628280-23-037441.md) | [649](/filings/0001628280-25-007740.md) | [656](/filings/0001628280-24-021191.md) | [686](/filings/0001628280-24-035235.md) | [684](/filings/0001628280-24-045365.md) | [756](/filings/0001628280-26-011213.md) | [745](/filings/0001628280-25-022716.md) | [658](/filings/0001628280-25-037931.md) | [725](/filings/0001628280-25-048944.md) | [729](/filings/0001628280-26-052646.md) | [687](/filings/0001628280-26-030602.md) | [797](/filings/0001628280-26-052646.md) |
| Total assets | $m | [4,725](/filings/0001628280-23-037441.md) | [4,509](/filings/0001628280-25-007740.md) | [4,504](/filings/0001628280-24-021191.md) | [4,511](/filings/0001628280-24-035235.md) | [4,470](/filings/0001628280-24-045365.md) | [4,487](/filings/0001628280-26-011213.md) | [4,437](/filings/0001628280-25-022716.md) | [4,351](/filings/0001628280-25-037931.md) | [4,384](/filings/0001628280-25-048944.md) | [4,317](/filings/0001628280-26-052646.md) | [4,424](/filings/0001628280-26-030602.md) | [4,341](/filings/0001628280-26-052646.md) |
| Current liabilities | $m | [448](/filings/0001628280-23-037441.md) | [537](/filings/0001628280-25-007740.md) | [493](/filings/0001628280-24-021191.md) | [596](/filings/0001628280-24-035235.md) | [553](/filings/0001628280-24-045365.md) | [567](/filings/0001628280-26-011213.md) | [577](/filings/0001628280-25-022716.md) | [622](/filings/0001628280-25-037931.md) | [671](/filings/0001628280-25-048944.md) | [712](/filings/0001628280-26-052646.md) | [743](/filings/0001628280-26-030602.md) | [709](/filings/0001628280-26-052646.md) |
| Total liabilities | $m | [2,985](/filings/0001628280-23-037441.md) | [3,042](/filings/0001628280-25-007740.md) | [3,033](/filings/0001628280-24-021191.md) | [3,018](/filings/0001628280-24-035235.md) | [2,946](/filings/0001628280-24-045365.md) | [2,909](/filings/0001628280-26-011213.md) | [2,863](/filings/0001628280-25-022716.md) | [2,757](/filings/0001628280-25-037931.md) | [2,759](/filings/0001628280-25-048944.md) | [2,790](/filings/0001628280-26-052646.md) | [2,910](/filings/0001628280-26-030602.md) | [2,955](/filings/0001628280-26-052646.md) |
| Long-term debt | $m | [2,127](/filings/0001628280-23-037441.md) | [2,095](/filings/0001628280-25-007740.md) | [2,159](/filings/0001628280-24-021191.md) | [2,040](/filings/0001628280-24-035235.md) | [2,014](/filings/0001628280-24-045365.md) | [1,965](/filings/0001628280-26-011213.md) | [1,941](/filings/0001628280-25-022716.md) | [1,793](/filings/0001628280-25-037931.md) | [1,744](/filings/0001628280-25-048944.md) | [1,716](/filings/0001628280-26-052646.md) | [1,799](/filings/0001628280-26-030602.md) | [1,880](/filings/0001628280-26-052646.md) |
| Current portion of debt | $m | [40.0](/filings/0001628280-23-037441.md) | [53.4](/filings/0001628280-25-007740.md) | [40.0](/filings/0001628280-24-021191.md) | [40.0](/filings/0001628280-24-035235.md) | [16.3](/filings/0001628280-24-045365.md) | [16.3](/filings/0001628280-26-011213.md) | [16.3](/filings/0001628280-25-022716.md) | [16.3](/filings/0001628280-25-037931.md) | [16.3](/filings/0001628280-25-048944.md) | [20.3](/filings/0001628280-26-052646.md) | [24.4](/filings/0001628280-26-030602.md) | [8.1](/filings/0001628280-26-052646.md) |
| Shareholders' equity | $m | [1,732](/filings/0001628280-23-037441.md) | [1,458](/filings/0001628280-25-007740.md) | [1,462](/filings/0001628280-24-021191.md) | [1,486](/filings/0001628280-24-035235.md) | [1,516](/filings/0001628280-24-045365.md) | [1,571](/filings/0001628280-26-011213.md) | [1,568](/filings/0001628280-25-022716.md) | [1,587](/filings/0001628280-25-037931.md) | [1,617](/filings/0001628280-25-048944.md) | [1,519](/filings/0001628280-26-052646.md) | [1,507](/filings/0001628280-26-030602.md) | [1,378](/filings/0001628280-26-052646.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [98.8 d](/filings/0001628280-24-045365.md) | [155 d](/filings/0001628280-26-011213.md) | [49.0](/filings/0001628280-25-022716.md) | [198 d](/filings/0001628280-25-037931.md) | [144 d](/filings/0001628280-25-048944.md) | [150 d](/filings/0001628280-26-011213.md) | [95.5](/filings/0001628280-26-030602.md) | [162 d](/filings/0001628280-26-052646.md) | [161 d](/filings/0001628280-25-048944.md) | [183 d](/filings/0001628280-26-011213.md) | [93.7](/filings/0001628280-26-030602.md) | [145 d](/filings/0001628280-26-052646.md) |
| Capital expenditure | $m | [77.1 d](/filings/0001628280-24-045365.md) | [88.6 d](/filings/0001628280-26-011213.md) | [87.9](/filings/0001628280-25-022716.md) | [81.3 d](/filings/0001628280-25-037931.md) | [59.6 d](/filings/0001628280-25-048944.md) | [77.3 d](/filings/0001628280-26-011213.md) | [95.6](/filings/0001628280-26-030602.md) | [88.7 d](/filings/0001628280-26-052646.md) | [94.2 d](/filings/0001628280-25-048944.md) | [104 d](/filings/0001628280-26-011213.md) | [121](/filings/0001628280-26-030602.md) | [166 d](/filings/0001628280-26-052646.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-045365.md) | [20.1 d](/filings/0001628280-26-011213.md) | [0.0](/filings/0001628280-24-021191.md) | [0.0 d](/filings/0001628280-24-035235.md) | [0.0 d](/filings/0001628280-24-045365.md) | [0.0 d](/filings/0001628280-26-011213.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [138](/filings/0001628280-23-037441.md) | [136](/filings/0001628280-24-021191.md) | [136](/filings/0001628280-24-035235.md) | [135](/filings/0001628280-24-045365.md) | [133](/filings/0001628280-25-022716.md) | [136](/filings/0001628280-25-037931.md) | [137](/filings/0001628280-25-048944.md) | [135](/filings/0001628280-26-030602.md) | [137](/filings/0001628280-26-052646.md) | [137](/filings/0001628280-25-048944.md) | [136](/filings/0001628280-26-030602.md) | [136](/filings/0001628280-26-052646.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 136,344,196 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052646.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.